LeadXpro AG

Swiss Biotech Association

Member

leadXpro is an emerging lead compound discovery company to unlock structure based drug design for challenging membrane protein drug targets. We capitalize on the preferred and proprietary access to Swiss large academic research facilities (SwissFEL, SLS for X-ray, C-CINA Uni Basel for cryo-EM).

http://www.leadxpro.com
+41 79 770 97 24
info@leadXpro.com
Michael Hennig, Prof. Dr.

Location

5234 Villigen, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

10-19

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Tenpoint Therapeutics GmbH

Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts shaping the regenerative ocular medicine revolution.
4051 Basel

Member

Oncodesign Services

Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vitro/in vivo pharmacology.
21000 Dijon

Member

Recolony AG

Recolony focuses on the development of cancer therapies based on microbial-derived products. These drugs have an enormous influence on our immune system, enhancing an immune reaction against cancer. With this approach, Recolony will develop a new class of drugs for the treatment of cancer.
Zürich

Member